Literature DB >> 9521069

Diminished expression of CD40 ligand may contribute to the defective humoral immunity in patients with MHC class II deficiency.

S Nonoyama1, A Etzioni, H Toru, D P Ruggerie, D Lewis, S Pollack, A Aruffo, J I Yata, H D Ochs.   

Abstract

Major histocompatibility complex (MHC) class II deficiency (bare lymphocyte syndrome, BLS) is a rare primary immunodeficiency classified as a subgroup of severe combined immunodeficiency. We studied T and B lymphocyte function by examining the CD40 ligand/CD40 system in three BLS patients from two unrelated families. CD40 ligand expression by maximally activated BLS T cells was diminished. This abnormality may represent immunological naïveté rather than a general T cell defect, since expression of activation marker CD69 and proliferative responses to PHA or anti-CD3 were normal, and BLS T cells primed and restimulated in vitro expressed normal amounts of CD40 ligand. BLS B cells proliferated and produced IgE if stimulated with anti-CD40 or soluble CD40 ligand and IL-4. Activation of BLS B cells with soluble CD40 ligand and IL-4 induced normal expression of activation markers, although MHC class II expression remained absent. Depressed antibody titers, lack of amplification and failure to undergo isotype switching in response to immunization with bacteriophage phi x 174 demonstrated defective T cell help. We conclude that BLS B cells are functionally normal if appropriately stimulated, and that the defective humoral immunity observed may be related to diminished expression of CD40 ligand on BLS T cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521069     DOI: 10.1002/(SICI)1521-4141(199802)28:02<589::AID-IMMU589>3.0.CO;2-J

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  1 in total

1.  Hypoxemic Bronchiolitis Related to Major Histocompatibility Class II Deficiency.

Authors:  S Hammami; H Besbès; S Hadded; K Lajmi; L Ghédira; Ch B Meriem; M N Guediche
Journal:  Case Rep Med       Date:  2013-08-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.